-
公开(公告)号：EP4414709A1
公开(公告)日：2024-08-14
申请号：EP22878706.5
申请日：2022-08-11
发明人： KIM, Seung Ku , KIM, Ki Tae
IPC分类号： G01N33/574 , G01N33/82 , G01N33/92 , G01N33/68 , G01N30/72
CPC分类号： G01N33/92 , G01N33/82 , G01N30/72 , G01N33/68 , G01N33/574
摘要： The present invention relates to biomarkers for cancer diagnosis and uses thereof, and more particularly to a composition for diagnosing or predicting cancer prognosis, comprising an agent for measuring levels of at least two biomarkers selected from the group consisting of Complement Component 7 (C7), Dodecanoyl-L-carnitine (DC), Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG) and Osteopontin in blood, and a method of using the biomarker to provide information about the diagnosis or prognosis of cancer.
In the present invention, it was confirmed that the level of complement component 7 (C7), dodecanoyl-L-carnitine (DC), lysophosphatidylcholine (LPC), histidine-rich glycoprotein (HRG), and/or osteopontin (OPN) in blood of lung and/or hepatic cancer patients has been found to have different patterns than that of normal individuals, and the combination of these markers has been shown to improve the diagnosis of various cancers, including lung or hepatic cancer. Accordingly, the biomarkers of the present invention can be useful in cancer diagnosis and prognosis.-
公开(公告)号：EP4365197A1
公开(公告)日：2024-05-08
申请号：EP21948581.0
申请日：2021-12-07
发明人： KIM, Seung Ku , KIM, Ki Tae
摘要： The present invention relates to a humanized antibody specific for CD47 and a pharmaceutical composition for preventing or treating a CD47-related disease comprising the same, and more particularly, a humanized antibody specific for CD47, and a CD47-overexpressing cell comprising the humanized antibody It relates to a pharmaceutical composition for preventing or treating diseases mediated by
In the present invention, 16 kinds of humanized antibodies were prepared using an antibody (3A5 antibody) that binds to CD47, and it was confirmed that the humanized anti-CD47 antibody specifically binds to the CD47 antigen.
In addition, the humanized anti-CD47 antibody of the present invention not only blocks CD47-SIRPα binding, but also promotes phagocytosis by macrophages by binding to cells overexpressing CD47, and inhibits the growth of CD47-expressing tumors. Therefore, it can be applied to the prevention or treatment of diseases or tumors in which the immune response by overexpression of CD47 is suppressed.
-
搜索结果
2 条记录 (耗时 0.014 秒)
